Transthyretin (ATTR or Prealbumin or TBPA or TTR) - Pipeline Review, H1 2016 - Global Markets Direct - Market Research

Transthyretin (ATTR or Prealbumin or TBPA or TTR) - Pipeline Review, H1 2016

Transthyretin (ATTR or Prealbumin or TBPA or TTR) - Pipeline Review, H1 2016 - Global Markets Direct - Market Research
Transthyretin (ATTR or Prealbumin or TBPA or TTR) - Pipeline Review, H1 2016
Published Jun 28, 2016
76 pages — Published Jun 28, 2016
Price US$ 3,500.00  |  Buy this Report Now

About This Report

  
Abstract:

Summary

Global Markets Directs, Transthyretin (ATTR or Prealbumin or TBPA or TTR) - Pipeline Review, H1 2016, provides in depth analysis on Transthyretin (ATTR or Prealbumin or TBPA or TTR) targeted pipeline therapeutics.

The report provides comprehensive information on the Transthyretin (ATTR or Prealbumin or TBPA or TTR), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Transthyretin (ATTR or Prealbumin or TBPA or TTR) targeted therapeutics development and features dormant and discontinued projects.

Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape for Transthyretin (ATTR or Prealbumin or TBPA or TTR)
- The report reviews Transthyretin (ATTR or Prealbumin or TBPA or TTR) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Transthyretin (ATTR or Prealbumin or TBPA or TTR) targeted therapeutics and enlists all their major and minor projects
- The report assesses Transthyretin (ATTR or Prealbumin or TBPA or TTR) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Transthyretin (ATTR or Prealbumin or TBPA or TTR) targeted therapeutics

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Transthyretin (ATTR or Prealbumin or TBPA or TTR)
- Identify the use of drugs for target identification and drug repurposing
- Identi

  
Source:
Document ID
GMDHC0074TDB
Industry
Format:
PDF Adobe Acrobat
Buy Now

Sections

TitleStarting PageNumber of Pages
Table of Contents24
  List of Tables51
  List of Figures51
Introduction61
  Global Markets Direct Report Coverage61
Transthyretin (ATTR or Prealbumin or TBPA or TTR) Overview71
Therapeutics Development83
  Transthyretin (ATTR or Prealbumin or TBPA or TTR) Products under Development by Stage of Development81
  Transthyretin (ATTR or Prealbumin or TBPA or TTR) Products under Development by Therapy Area91
  Transthyretin (ATTR or Prealbumin or TBPA or TTR) Products under Development by Indication101
Transthyretin (ATTR or Prealbumin or TBPA or TTR) Pipeline Products Glance112
  Late Stage Products111
  Early Stage Products121
Transthyretin (ATTR or Prealbumin or TBPA or TTR) Products under Development by Companies132
Transthyretin (ATTR or Prealbumin or TBPA or TTR) Products under Development by Universities/Institutes152
Transthyretin (ATTR or Prealbumin or TBPA or TTR) Therapeutics Assessment176
  Assessment by Monotherapy/Combination Products171
  Assessment by Mechanism of Action181
  Assessment by Route of Administration192
  Assessment by Molecule Type212
Transthyretin (ATTR or Prealbumin or TBPA or TTR) Companies Involved in Therapeutics Development237
  Alnylam Pharmaceuticals, Inc.231
  Arcturus Therapeutics, Inc241
  Neurimmune Holding AG251
  Pfizer Inc.261
  Prothena Corporation Plc271
  Regeneron Pharmaceuticals, Inc.281
  SOM Innovation Biotech SL291
Transthyretin (ATTR or Prealbumin or TBPA or TTR) Drug Profiles3029
  ALN-TTRsc02 Drug Profile301
  EDE-1307 Drug Profile311
  inotersen sodium Drug Profile324
  LUNAR-TTR Drug Profile361
  Monoclonal Antibodies to Inhibit Transthyretin for Amyloidosis Drug Profile371
  Monoclonal Antibody to Inhibit ATTR for Familial Amyloid Polyneuropathy Drug Profile381
  NI-301 Drug Profile391
  Oligonucleotides to Inhibit Transthyretin for Amyloidosis Drug Profile401
  patisiran Drug Profile418
  revusiran Drug Profile494
  Small Molecules to Inhibit Transthyretin for Familial Amyloid Polyneuropathy Drug Profile531
  tafamidis meglumine Drug Profile543
  tolcapone Drug Profile572
Transthyretin (ATTR or Prealbumin or TBPA or TTR) Dormant Projects591
Transthyretin (ATTR or Prealbumin or TBPA or TTR) Featured News &Press Releases6015
  Jun 09, 2016: Alnylam Initiates Phase 1 Clinical Trial for ALN-TTRsc02, an Investigational RNAi Therapeutic for the Treatment of TTR-Mediated Amyloidosis601
  May 26, 2016: Ionis Pharmaceuticals Provides Update on IONIS-TTR Rx Program601
  Apr 20, 2016: Alnylam Reports Complete 18-Month Data from Ongoing Phase 2 Open-Label Extension Study of Patisiran, an Investigational RNAi Therapeutic Targeting Transthyretin for the Treatment of Hereditary ATTR Amyloidosis with Polyneuropathy (hATTR-PN)612
  Apr 07, 2016: Ionis Pharmaceuticals Provides Update on IONIS-TTRRX Program631
  Feb 01, 2016: Alnylam Completes Enrollment in APOLLO Phase 3 Study with Patisiran, an Investigational RNAi Therapeutic for Patients with Transthyretin (TTR)-Mediated Amyloidosis (ATTR Amyloidosis)641
  Dec 17, 2015: Isis Pharmaceuticals Announces Initiation of an Investigator-Sponsored Phase 2 Study of ISIS-TTR Rx in Patients with TTR Cardiomyopathy Amyloidosis651
  Nov 12, 2015: SOM Biotech and Vall d Hebron successfully complete a clinical trial in patients with TTR amyloidosis661
  Nov 03, 2015: Alnylam Reports Positive Results from Ongoing Phase 2 Open-Label Extension Studies for Patisiran in Development for the Treatment of Transthyretin (TTR)-Mediated Amyloidosis (ATTR Amyloidosis)662
  Nov 03, 2015: Isis Pharmaceuticals Reports an Update on ISIS-TTR Rx, Including Positive Data from Multiple Clinical Studies, Presented at the EC-ATTR Meeting682
  Nov 03, 2015: Alnylam Reports Positive Results from Ongoing Phase 2 Open-Label Extension Studies for Revusiran, in Development for the Treatment of Transthyretin (TTR)-Mediated Amyloidosis701
  Oct 27, 2015: Isis Pharmaceuticals to Host Webcast to Review ISIS-TTR Data Presented at 1st European Congress of Hereditary ATTR Amyloidosis and Provide Phase 3 Development Plan Update711
  Oct 14, 2015: Alnylam Demonstrates Continued Commitment to Transthyretin-Mediated Amyloidosis Patients with Advancement of ALN-TTRsc02, an Investigational RNAi Therapeutic with Potential for Low Volume, Once Quarterly, Subcutaneous Dose Regimen711
  Oct 01, 2015: 1st European Congress on Hereditary ATTR Amyloidosis721
  Sep 28, 2015: Alnylam and Collaborators Report First-Ever Evidence that Patisiran Reduces Pathogenic, Misfolded Transthyretin Monomers and Oligomers in TTR-Mediated Amyloidosis Patients with Familial Amyloidotic Polyneuropathy722
  Sep 15, 2015: Phase IIa Clinical Trial for TTR Amyloidosis successfully completed741
Appendix752
  Methodology751
  Coverage751
  Secondary Research751
  Primary Research751
  Expert Panel Validation751
  Contact Us751
  Disclaimer761

Table Of Contents

Global Markets Direct - Market Research—Global Markets Direct is a leading provider of global business intelligence and market analysis. It publishes a range of high quality market reports created by its large research and analysis capability and drawing from its extensive unique databases of industry-specific information.

About the Author


Cite this Report

  
MLA:
Global Markets Direct - Market Research. "Transthyretin (ATTR or Prealbumin or TBPA or TTR) - Pipeline Review, H1 2016" Jun 28, 2016. Alacra Store. Nov 16, 2026. <http://www.alacrastore.com/storecontent/Global-Markets-Direct-Market-Research/Transthyretin-ATTR-or-Prealbumin-or-TBPA-or-TTR-Pipeline-Review-H1-2016-2088-16024>
  
APA:
Global Markets Direct - Market Research. (2016). Transthyretin (ATTR or Prealbumin or TBPA or TTR) - Pipeline Review, H1 2016 Jun 28, 2016. New York, NY: Alacra Store. Retrieved Nov 16, 2026 from <http://www.alacrastore.com/storecontent/Global-Markets-Direct-Market-Research/Transthyretin-ATTR-or-Prealbumin-or-TBPA-or-TTR-Pipeline-Review-H1-2016-2088-16024>
  
US$ 3,500.00
$  £  €
Have a Question?

Any questions about the report you're considering? Our Customer Service Team can help! Or visit our FAQs.

More Research

Search all our Market Research from one place.